Aclaris stock falls after atopic dermatitis trial fails

STREETINSIDER.COMNov 16, 4:33 PM UTC

Key insights

  • Aclaris Therapeutics (ACRS) shares declined after its Phase 2 ADMIRATION trial for atopic dermatitis failed to meet primary and secondary endpoints. The company stated the results do not alter development priorities, which include oral kinase inhibitors and a bispecific antibody. Aclaris also initiated a Phase 2b trial for modzatinib in lichen planus, with results expected in late 2027.
Aclaris stock falls after atopic dermatitis trial fails

Investing.com -- Aclaris Therapeutics Inc (NASDAQ: ACRS) shares fell 6% in Monday trade after the company announced its Phase 2 ADMIRATION trial for atopic dermatitis treatment failed to meet its primary and secondary endpoints.

The trial evaluated bosakitug (ATI-045), a humanized anti-thymic stromal lymphopoietin monoclonal antibody, in patients with moderate-to-severe atopic dermatitis. The primary endpoint measured percent change in Eczema Area and Severity Index score from baseline at Week 24. While pharmacodynamic results showed target engagement of TSLP and downregulation of biomarkers related to immune activation including Th1, Th2, and Th17, the drug was generally well tolerated.

"We are disappointed that the ADMIRATION trial did not overcome the historical challenges of addressing atopic dermatitis with an anti-TSLP monoclonal antibody alone," said Dr. Neal Walker, Chief Executive Officer of Aclaris.

The company stated the results do not change its development priorities, which remain focused on oral kinase inhibitors and anti-TSLP/IL-4Rα bispecific antibody ATI-052.

Separately, Aclaris announced it has initiated a Phase 2b ALPHA trial of modzatinib (ATI-2138) in patients with moderate-to-severe lichen planus. The randomized, double-blind, placebo-controlled trial will enroll approximately 100 participants, with the first cohort consisting of patients with oral erosive lichen planus. The U.S. Food and Drug Administration has granted Fast Track Designation for modzatinib for moderate-to-severe lichen planus.

The company expects top line results from the oral erosive lichen planus cohort in the second half of 2027. Aclaris also plans to file an IND for ATI-9494, an oral ITK inhibitor, this quarter and initiate a Phase 2b trial of ATI-052 in eosinophilic esophagitis in the first quarter of 2027.

Original Article

Continue reading on STREETINSIDER.COM

Related Articles